Literature DB >> 1968359

Multidrug resistance phenotype of human BRO melanoma cells transfected with a wild-type human mdr1 complementary DNA.

C R Lincke1, A M van der Bliek, G J Schuurhuis, T van der Velde-Koerts, J J Smit, P Borst.   

Abstract

We have transfected a eukaryotic expression vector containing a mdr1 complementary DNA isolated from normal human liver into human BRO melanoma cells to study the drug-resistant phenotype produced by the exclusive overexpression of normal human mdr1 P-glycoprotein. The drug resistance pattern of mdr1-transfected clones includes relatively high resistance to gramicidin D (about 300-fold), vincristine (about 100-fold), and actinomycin D (about 100-fold) and a lower degree of resistance to doxorubicin (about 10-fold), VP16-213 (about 10-fold), and colchicine (about 6-fold). The transfectants did not exhibit resistance to trimetrexate, cis-platinum, mitomycin C, 1-beta-D-arabinofuranosylcytosine, bleomycin, G418, or magainin-2-amide; they were slightly more sensitive to verapamil (2-fold) but not to Triton X-100. As in other multidrug-resistant cell lines, resistance to vincristine could be reversed by verapamil and, more effectively, by cyclosporin A. Chloroquine only marginally increased drug sensitivity in mdr1-transfected cells. Gramicidin D resistance was also reversed by verapamil, suggesting that the mechanism of resistance to this polypeptide antibiotic is similar to that of other drugs transported by P-glycoprotein. Thus, expression of the wild-type mdr1 complementary DNA induces a drug-resistant phenotype similar to that induced by mdr1 complementary DNAs isolated from drug-resistant cell lines with relatively low colchicine resistance. As other cell lines may display a different pattern of drug resistance, it is clear that other resistance mechanisms or cell type-specific factors may modulate the resistance. mdr1-transfected cell lines provide a convenient tool for the identification of P-glycoprotein-mediated phenomena.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1968359

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  24 in total

Review 1.  The use of therapeutic peptides to target and to kill cancer cells.

Authors:  R J Boohaker; M W Lee; P Vishnubhotla; J M Perez; A R Khaled
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

Review 2.  The biology of the P-glycoproteins.

Authors:  C R Leveille-Webster; I M Arias
Journal:  J Membr Biol       Date:  1995-01       Impact factor: 1.843

Review 3.  Cellular models for multiple drug resistance in cancer.

Authors:  M Clynes
Journal:  In Vitro Cell Dev Biol       Date:  1993-03

4.  Peripheral neuropathy in mice transgenic for a human MDR3 P-glycoprotein mini-gene.

Authors:  J J Smit; F Baas; J E Hoogendijk; G H Jansen; M A van der Valk; A H Schinkel; A J Berns; D Acton; K Nooter; H Burger; S J Smith; P Borst
Journal:  J Neurosci       Date:  1996-10-15       Impact factor: 6.167

5.  P-glycoprotein is expressed in the mineralizing regions of the skeleton.

Authors:  D C Mangham; A Cannon; S Komiya; R L Gendron; K Dunussi; M C Gebhardt; H J Mankin; R J Arceci
Journal:  Calcif Tissue Int       Date:  1996-03       Impact factor: 4.333

6.  Functions of yeast helicase Ssl2p that are essential for viability are also involved in protection from the toxicity of adriamycin.

Authors:  Takemitsu Furuchi; Tsutomu Takahashi; Shogo Tanaka; Katsushi Nitta; Akira Naganuma
Journal:  Nucleic Acids Res       Date:  2004-05-11       Impact factor: 16.971

7.  MDR-1 gene expression, anthracycline retention and cytotoxicity in human lung-tumor cells from refractory patients.

Authors:  C Ramachandran; A Sauerteig; K S Sridhar; R J Thurer; A Krishan
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

8.  Mice with homozygous disruption of the mdr2 P-glycoprotein gene. A novel animal model for studies of nonsuppurative inflammatory cholangitis and hepatocarcinogenesis.

Authors:  T H Mauad; C M van Nieuwkerk; K P Dingemans; J J Smit; A H Schinkel; R G Notenboom; M A van den Bergh Weerman; R P Verkruisen; A K Groen; R P Oude Elferink
Journal:  Am J Pathol       Date:  1994-11       Impact factor: 4.307

Review 9.  Human cell lines as models for multidrug resistance in solid tumours.

Authors:  M Clynes; M Heenan; K Hall
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

10.  Increased sensitivity to gemcitabine of P-glycoprotein and multidrug resistance-associated protein-overexpressing human cancer cell lines.

Authors:  A M Bergman; H M Pinedo; I Talianidis; G Veerman; W J P Loves; C L van der Wilt; G J Peters
Journal:  Br J Cancer       Date:  2003-06-16       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.